3D 바이오프린팅 (2018 - 2028년): 기술, 시장, 전망: IDTechEx

This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.

If you have previously purchased this report then please use the download links on the right to download the files.

3D 바이오프린팅 (2018 - 2028년): 기술, 시장, 전망

화장품 및 소비재 테스트, 약물 개발 및 재생 의학의 기회


모두 보기 설명 목차, 표 및 그림 목록 가격 Related Content
이 보고서는 3D 바이오프린팅에 사용되는 기술과 3D 바이오프린팅 조직의 주요 응용분야를 다루며 또한 향후 재생 의학의 적용에 중점을 둔다. 이 보고서에서는 3D 바이오프린팅 기술, 현재의 동인, 동향 및 과제의 이점에 대해 설명한다. 3D 바이오프린팅은 2028년까지 19억 달러 시장이 될 것으로 추정된다.
Interest in 3D bioprinting has been gaining momentum in recent years, both in the academic and commercial settings. Between 2014 and 2015, the market welcomed numerous 3D bioprinting companies, and new start-ups, spin-outs, and subsidiaries are continuing to emerge. Though investment in the field has been driven on by the futuristic goal of providing solutions for regenerative by way of fabricating organs for transplant, more realistic applications in product development and testing have shown great promise and are already being marketed. Over 2016, several 3D bioprinting companies saw a doubling of revenue, and comparable results are anticipated for the next few years. Given these market trends, IDTechEx forecasts that the global market for 3D bioprinting will reach a value of $1.9 billion by the year 2028.
 
Technology and Applications
3D bioprinting can be defined in a variety of ways, and each definition includes and excludes large swathes of key biotechnology markets. In this report, IDTechEx has defined 3D bioprinting as the deposition of living cells in a spatially controlled manner in the absence of any pre-existing scaffold and in more than a single layer. Under this definition, 3D bioprinters are currently based on four main printhead technologies:
 
  • Inkjet
  • Extrusion
  • Laser-induced forward transfer
  • Microvalve
 
This report profiles each technology and its subtypes, and provides key specifications, vendors, and SWOT analyses. This report also introduces and discusses 3D bioprinting technologies of microfluidic chip, microneedle array, 2-photon polymerization, and cell electrospinning amongst others. Technologies and considerations relevant to the 3D bioprinting process, such as software, bioink (including cell selection, growth factors, and scaffold materials), and post-printing maturation are also discussed.
 
Current and future applications for 3D bioprinting discussed in this report include:
 
  • Testing of cosmetics and other consumer goods
  • Drug screening
  • Personalised medicine
  • Regenerative medicine
  • Cell-based biosensors
  • Food and other animal products
  • Education
  • Academic research
  • Bionics
 
Regenerative Medicine
Special attention is paid to regenerative medicine in this report, as not only does it have the potential to be the largest application for 3D bioprinting in the future, but also one with the highest impact. This report analyses how 3D bioprinting can be applied to regenerative medicine, and focuses on the following tissue types:
 
  • Bone and cartilage
  • Skin
  • Dental
  • Vasculature
  • Complex organs
 
Additionally, discussion of current progress in bringing 3D bioprinted tissues to the clinic is provided, as well future hurdles to be faced. A roadmap of 3D bioprinting in regenerative medicine to the year 2050 is provided.
 
Forecasts
This report forecasts the overall 3D bioprinting market to 2028, with in depth discussion of key trends in the short term (2018 - 2022), and those expected in the long term (2023 - 2028). Market forecasts to 2028 are also provided for the 3D bioprinter market segmented by price point, and the 3D bioprinted tissue market segmented by tissue application.
IDTechEx의 분석가 액세스
모든 보고서 구입에는 전문가 분석가와의 최대 30분의 전화통화 시간이 포함되어, 보고서의 주요 결과를 귀하가 제시하는 비즈니스 문제에 연결하도록 돕습니다. 이 전화통화는 보고서를 구매한 후 3개월 이내에 사용해야합니다.
추가 정보
이 보고서에 대해 궁금한 점이 있으시면 언제든지 research@IDTechEx.com으로 보고서 팀에 문의하거나, 영업 관리자에게 문의하십시오

AMERICAS (USA): +1 617 577 7890
ASIA (Japan): +81 3 3216 7209
ASIA (Korea): +82 10 3896 6219
EUROPE (UK) +44 1223 812300
Table of Contents
1.EXECUTIVE SUMMARY
1.1.Overview
1.2.Key 3D Bioprinter Manufacturers
1.3.3D Bioprinting Service Bureaus
1.4.High Profile Partnerships
1.5.3D Bioprinter Market Forecast 2018 - 2028
1.6.3D Bioprinted Tissue Market Forecast 2018 - 2028
1.7.Key Drivers
1.8.Key Challenges
2.INTRODUCTION
2.1.Report Scope / 3D Bioprinting Definition
2.2.3D Bioprinting Process
2.3.3D Bioprinting Process: Discussion
2.4.3D Cell Culture Advantages
2.5.3D Bioprinting Advantages
2.6.Key Driver: Regenerative Medicine
2.7.Key Driver: Unmet Need in Organs for Transplant
2.8.Key Driver: Product Testing in Medicine
2.9.Key Driver: Avoiding Costly Drug Trial Failures
2.10.Key Driver: Product Testing in Consumer Products
2.11.Major Bioprinting Firsts
2.12.Key Trends: 3D Bioprinters
2.13.Key Trends: Bioprinted Tissues
2.14.Key Competing Technologies
2.15.Current Biological Challenges
2.16.Regulatory Hurdles
2.17.3D Bioprinting SWOT Analysis
3.3D BIOPRINTER TECHNOLOGIES
3.1.From 3D Printing to 3D Bioprinting
3.2.3D Bioprinting Technologies
3.3.Comparison of Key Specifications
3.4.3D Bioprinting Technology Comparison
3.5.Inkjet: Introduction
3.6.Inkjet: Key Specifications
3.7.Inkjet: Thermal
3.8.Inkjet: Piezoelectric
3.9.Inkjet: Advantages
3.10.Inkjet: Challenges
3.11.Inkjet: SWOT Analysis
3.12.Extrusion: Introduction
3.13.Extrusion: Key Specifications
3.14.Extrusion: Pneumatic
3.15.Extrusion: Mechanical
3.16.Extrusion: Advantages
3.17.Extrusion: Challenges
3.18.Extrusion: SWOT Analysis
3.19.Laser: Introduction
3.20.LIFT: Key Specifications
3.21.LIFT: Laser-Induced Forward Transfer
3.22.LIFT: Advantages
3.23.LIFT: Challenges
3.24.LIFT: SWOT Analysis
3.25.Microvalve: Introduction
3.26.Microvalve: Key Specifications
3.27.Microvalve: Solenoid
3.28.Microvalve: Advantages
3.29.Microvalve: Challenges
3.30.Microvalve: SWOT Analysis
3.31.Other Technologies
3.32.Microfluidic Chip
3.33.In-Air Microfluidics
3.34.Turnstile
3.35.Microneedle Array
3.36.2-Photon Polymerization
3.37.Cell Electrospinning
3.38.Microscale Continuous Optical Bioprinting
3.39.Paramagnetic and Acoustic
3.40.Industry-wide Technical Challenges
3.41.The Ideal 3D Bioprinter
3.42.Future Technological Directions
4.RELATED TECHNOLOGIES
4.1.Related Technologies
4.2.3D Bioprinting Software
4.3.Bioink Preparation
4.4.Cell Selection
4.5.Cell Selection: Regenerative Medicine
4.6.Cell Selection: Bacteria
4.7.Growth Factors and Other Additives
4.8.Matrix Materials
4.9.Matrix Materials: Companies
4.10.The Ideal Scaffold Material
4.11.Cell Spheroid Printing
4.12.Maturation
5.APPLICATIONS
5.1.Introduction
5.2.Testing of Cosmetics and Other Consumer Goods
5.3.Testing of Cosmetics and Other Consumer Goods: Skin
5.4.Drug Screening
5.5.Drug Screening: Drug Development Process
5.6.Drug Screening: Benefits of 3D Bioprinting
5.7.Drug Screening: Cancer
5.8.Personalised Medicine
5.9.Regenerative Medicine
5.10.Regenerative Medicine: Tissue Roadmap
5.11.Regenerative Medicine: Bone and cartilage
5.12.Regenerative Medicine: Skin
5.13.Regenerative Medicine: Dental
5.14.Regenerative Medicine: Vasculature
5.15.Regenerative Medicine: Complex Organs
5.16.Regenerative Medicine: Mini-Organs
5.17.Cell-Based Biosensors
5.18.Food and Other Animal Products
5.19.Education
5.20.Academic Research
5.21.Bionics
6.MARKETS AND FORECASTS
6.1.Introduction
6.2.Growing 3D Bioprinting Market
6.3.Key 3D Bioprinter Manufacturers
6.4.3D Bioprinting Service Bureaus
6.5.High Profile Partnerships
6.6.Research Groups and Centers
6.7.Market Barriers
6.8.Key Losers
6.9.Forecasts
6.10.Overall 3D Bioprinting Market Forecast 2018 - 2028
6.11.Overall 3D Bioprinting Market Forecast: Short and Long Term
6.12.3D Bioprinting Value Chain
6.13.3D Bioprinting Value Chain: Discussion
6.14.3D Bioprinter Manufacturers
6.15.3D Bioprinters by Cost and Technology
6.16.3D Bioprinter Market Forecast 2018 - 2028
6.17.3D Bioprinter Market Forecast: Short Term
6.18.3D Bioprinter Market Forecast: Long Term
6.19.3D Bioprinted Tissue Forecast 2018 - 2028
6.20.3D Bioprinted Tissue Forecast: Consumer Products
6.21.3D Bioprinted Tissue Forecast: Pharmaceuticals
6.22.3D Bioprinted Tissue Forecast: Others
7.REGENERATIVE MEDICINE
7.1.Introduction
7.2.Regulatory Hurdles
7.3.Regenerative Medicine Advanced Therapy Designation
7.4.RMAT: 1 year Later
7.5.Ethics
7.6.Scams and Schemes
7.7.From Lab to Clinic
7.8.3D Bioprinting Roadmap to 2050
8.APPENDIX
8.1.List of Abbreviations
8.2.List of 3D Bioprinting Companies
9.LIST OF COMPANY PROFILES
9.1.3D Bioprinting Solutions/Vivax Bio
9.2.3Dynamic Systems
9.3.Aether
9.4.Aspect Biosystems
9.5.BioBots (now Allevi)
9.6.BioDan Group
9.7.BIOLIFE4D
9.8.Cellbrick
9.9.Cellenion
9.10.Cellink
9.11.Digilab
9.12.GeSiM
9.13.Microdrop Technologies
9.14.MicroFab Technologies
9.15.Organovo
9.16.PeptiGelDesign
9.17.Poietis
9.18.Prellis Biologics
9.19.Regemat 3D
9.20.regenHu
9.21.SE3D
9.22.Sichuan Revotek
 

보고서 통계

슬라이드 225
Companies 21
전망 2028
 
 
 
 

Subscription Enquiry